BusinessAgile Therapeutics Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 6, 2017, 9:20 PM UTC
BusinessNeos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and OlderBy Nasdaq OMXSep 15, 2017, 8:39 PM UTC
BusinessAdamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsBy Nasdaq OMXAug 24, 2017, 8:16 PM UTC
BusinessAdamas Reports Recent Achievements and Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 8, 2017, 8:01 PM UTC
BusinessAdamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017By Nasdaq OMXAug 1, 2017, 6:33 PM UTC
BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
BusinessAdamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA NeurologyBy Nasdaq OMXJun 12, 2017, 8:01 PM UTC
